Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Adults 18 to 64 Years Old with Medical Conditions and Other Factors That Increase Risk of Pneumococcal Disease

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2022 Nov 11

PMID 36368038

Authors

Charu Sabharwal

Vani Sundaraiyer

Yahong Peng

Lisa Moyer

Todd J Belanger

Bradford D Gessner

Luis Jodar

Kathrin U Jansen

William C Gruber

Daniel A Scott

Wendy Watson

Affiliations

Soon will be listed here.

Abstract

NCT03760146, NCT03828617.

References

Baxter R, Yee A, Aukes L, Snow V, Fireman B, Atkinson B . Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016; 34(36):4293-7. DOI: 10.1016/j.vaccine.2016.07.003. View

Zimmermann P, Curtis N . Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019; 32(2). PMC: 6431125. DOI: 10.1128/CMR.00084-18. View

Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X . Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years. Clin Infect Dis. 2021; 75(3):390-398. PMC: 9427137. DOI: 10.1093/cid/ciab990. View

Klein N, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully I . A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021; 39(38):5428-5435. DOI: 10.1016/j.vaccine.2021.07.004. View

Vadlamudi N, Chen A, Marra F . Impact of the 13-Valent Pneumococcal Conjugate Vaccine Among Adults: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018; 69(1):34-49. DOI: 10.1093/cid/ciy872. View

McLaughlin J, Jiang Q, Isturiz R, Sings H, Swerdlow D, Gessner B . Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis. 2018; 67(10):1498-1506. PMC: 6206101. DOI: 10.1093/cid/ciy312. View

van der Linden M, Imohl M, Perniciaro S . Limited indirect effects of an infant pneumococcal vaccination program in an aging population. PLoS One. 2019; 14(8):e0220453. PMC: 6675109. DOI: 10.1371/journal.pone.0220453. View

Metcalf B, Gertz Jr R, Gladstone R, Walker H, Sherwood L, Jackson D . Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2015; 22(1):60.e9-60.e29. PMC: 4721534. DOI: 10.1016/j.cmi.2015.08.027. View

de Miguel S, Domenech M, Gonzalez-Camacho F, Sempere J, Vicioso D, Sanz J . Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era. Clin Infect Dis. 2020; 73(11):e3778-e3787. DOI: 10.1093/cid/ciaa1483. View

10.

Arcavi L, Benowitz N . Cigarette smoking and infection. Arch Intern Med. 2004; 164(20):2206-16. DOI: 10.1001/archinte.164.20.2206. View

11.

Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S . Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis. 2016; 62(9):1119-25. DOI: 10.1093/cid/ciw067. View

12.

Torres A, Blasi F, Dartois N, Akova M . Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015; 70(10):984-9. PMC: 4602259. DOI: 10.1136/thoraxjnl-2015-206780. View

13.

Moore M, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett N . Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15(3):301-9. PMC: 4876855. DOI: 10.1016/S1473-3099(14)71081-3. View

14.

Lewnard J, Bruxvoort K, Fischer H, Hong V, Grant L, Jodar L . Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults. Clin Infect Dis. 2021; 75(5):832-841. DOI: 10.1093/cid/ciab1051. View

15.

Suaya J, Jiang Q, Scott D, Gruber W, Webber C, Schmoele-Thoma B . Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018; 36(11):1477-1483. DOI: 10.1016/j.vaccine.2018.01.049. View

16.

Weycker D, Farkouh R, Strutton D, Edelsberg J, Shea K, Pelton S . Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016; 16:182. PMC: 4867996. DOI: 10.1186/s12913-016-1432-4. View

17.

Fukuda H, Onizuka H, Nishimura N, Kiyohara K . Risk factors for pneumococcal disease in persons with chronic medical conditions: Results from the LIFE Study. Int J Infect Dis. 2022; 116:216-222. DOI: 10.1016/j.ijid.2021.12.365. View

18.

Kobayashi M, Farrar J, Gierke R, Britton A, Childs L, Leidner A . Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(4):109-117. PMC: 9351524. DOI: 10.15585/mmwr.mm7104a1. View

19.

Blasi F, Mantero M, Santus P, Tarsia P . Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012; 18 Suppl 5:7-14. DOI: 10.1111/j.1469-0691.2012.03937.x. View

20.

Grant L, Slack M, Yan Q, Trzcinski K, Barratt J, Sobczyk E . The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy. Expert Rev Vaccines. 2021; 20(6):691-705. DOI: 10.1080/14760584.2021.1921579. View